Can analysts adopt a bullish outlook for Chiasma, Inc. (NASDAQ:CHMA)?

March 14, 2018 - By reb123z

 Can analysts adopt a bullish outlook for Chiasma, Inc. (NASDAQ:CHMA)?

Chiasma, Inc. (NASDAQ:CHMA) Ratings Coverage

Among 3 analysts covering Chiasma (NASDAQ:CHMA), 1 have Buy rating, 1 Sell and 1 Hold. Therefore 33% are positive. Chiasma had 6 analyst reports since August 10, 2015 according to SRatingsIntel. The rating was initiated by William Blair with “Outperform” on Monday, August 10. Cowen & Co initiated the shares of CHMA in report on Monday, August 10 with “Outperform” rating. Barclays Capital downgraded it to “Underweight” rating and $2.50 target in Tuesday, January 17 report. The stock of Chiasma, Inc. (NASDAQ:CHMA) has “Equal-Weight” rating given on Monday, April 25 by Barclays Capital. The rating was downgraded by William Blair on Monday, April 18 to “Market Perform”. The stock has “Overweight” rating by Barclays Capital on Monday, August 10. Below is a list of Chiasma, Inc. (NASDAQ:CHMA) latest ratings and price target changes.

The stock decreased 1.59% or $0.03 during the last trading session, reaching $1.55. About 12,347 shares traded. Chiasma, Inc. (NASDAQ:CHMA) has declined 48.76% since March 14, 2017 and is downtrending. It has underperformed by 65.46% the S&P500.

Chiasma, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing oral forms of therapies using transient permeability enhancer technology platform. The company has market cap of $37.79 million. The firm offers octreotide capsules, which is in Phase III clinical trial for the treatment of acromegaly, a condition that results in the bodyÂ’s production of excess growth hormone under the MYCAPSSA name. It currently has negative earnings.

More notable recent Chiasma, Inc. (NASDAQ:CHMA) news were published by: which released: “Chiasma Inc.” on April 03, 2016, also with their article: “Chiasma to Present at the Cowen and Company 38th Annual Health Care Conference” published on February 28, 2018, published: “Chiasma Inc. CHMA (US: Nasdaq)” on July 10, 2015. More interesting news about Chiasma, Inc. (NASDAQ:CHMA) were released by: and their article: “Chiasma Honors Patients, Researchers for Rare Disease Day 2018” published on February 28, 2018 as well as‘s news article titled: “Chiasma Provides Update Regarding FDA’s Complete Response Letter for Mycapssa …” with publication date: April 18, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.